Letters Indian generic drug production

Benefits of EU-India free trade agreement

BMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d2439 (Published 18 April 2011) Cite this as: BMJ 2011;342:d2439
  1. Brian Ager, director general1
  1. 1European Federation of the Pharmaceutical Industries and Associations, Brussels, Belgium
  1. brianager{at}efpia.org
  • Competing interests: None declared.

Love repeats many myths surrounding the free trade agreement (FTA) and ignores the benefits to India from balanced provisions for intellectual property.1 He says that negotiations are being conducted “in secrecy,” but then criticises their alleged content. He offers hyperbole and straw men: “The EU has asked India to sacrifice access to life saving drugs …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe